Quick Answer
Rein Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Rein Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue (ASC 606) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$49.87M +20.7% |
-$62.88M -299.7% |
-$15.73M +42.4% |
-$27.33M -4.5% |
-$26.16M +4.3% |
-$27.33M +6.9% |
| Diluted EPS | -$1.96 +44.2% |
-$3.51 -2.6% |
-$3.42 +43.2% |
-$6.02 -2.2% |
-$5.89 | — |
| Total Assets | $24.16M -61.2% |
$62.19M -41.3% |
$106.01M +381.7% |
$22.01M -54.6% |
$48.48M +196.7% |
$16.34M -38.3% |
| Cash and Equivalents | $3.21M -75.0% |
$12.87M -25.8% |
$17.34M +233.8% |
$5.19M +44.3% |
$3.60M -48.9% |
$7.05M +32.7% |
| Stockholders Equity | $16.92M -68.9% |
$54.39M -44.7% |
$98.30M +427.8% |
$18.62M -57.6% |
$43.90M +261.0% |
$12.16M -24.2% |
| R&D Expense | $11.03M -22.6% |
$14.25M +257.0% |
$3.99M -77.8% |
$17.97M +5.6% |
$17.01M +52.3% |
$11.17M -36.8% |
| Operating Income | -$50.63M +22.2% |
-$65.11M -300.0% |
-$16.28M +41.1% |
-$27.65M -3.9% |
-$26.61M -29.8% |
-$20.50M +31.6% |
| Shares Outstanding | 27.55M +27.2% |
21.67M +343.5% |
4.89M +7.6% |
4.54M +0.3% |
4.53M -89.7% |
43.80M +57.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$5.58M | +4.5% | +18.2% |
| Diluted EPS | September 30, 2025 | -$0.21 | +22.2% | +25.0% |
| Total Assets | September 30, 2025 | $53.71M | -48.5% | -6.6% |
| Cash and Equivalents | September 30, 2025 | $4.05M | -77.1% | -29.3% |
| Stockholders Equity | September 30, 2025 | $46.19M | -51.5% | -3.8% |
| R&D Expense | September 30, 2025 | $1.68M | -54.8% | -60.8% |
| Operating Income | September 30, 2025 | -$5.49M | +9.5% | +20.1% |
| Shares Outstanding | September 30, 2025 | 25.14M | +16.0% | +9.1% |
- Rein Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Rein Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Rein Therapeutics, Inc. reported Net Income of -$49.87 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed an increase of +20.7% in Net Income compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Diluted EPS of $1.96 per share (loss) for fiscal year 2025.
- Rein Therapeutics, Inc. showed an increase of +44.2% in Diluted EPS compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Total Assets of $24.16 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed a decrease of -61.2% in Total Assets compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Cash and Equivalents of $3.21 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed a decrease of -75.0% in Cash and Equivalents compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Stockholders Equity of $16.92 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed a decrease of -68.9% in Stockholders Equity compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported R&D Expense of $11.03 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed a decrease of -22.6% in R&D Expense compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Operating Income of -$50.63 million for fiscal year 2025.
- Rein Therapeutics, Inc. showed an increase of +22.2% in Operating Income compared to the prior fiscal year.
- Rein Therapeutics, Inc. reported Shares Outstanding of 27.55 million shares for fiscal year 2025.
- Rein Therapeutics, Inc. showed an increase of +27.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: